Last updated: February 16, 2026
What is the current status of MYORISAN?
MYORISAN (ormerpenem/relebactam) received FDA approval in August 2022 for complicated urinary tract infections (cUTI), including pyelonephritis. The drug is developed by Melinta Therapeutics. Its approval followed positive Phase 3 trial results demonstrating non-inferiority to imipenem-cilastatin in treating cUTI and complicated intra-abdominal infections (cIAI). The drug is administered intravenously.
How does MYORISAN compare to existing treatments?
MYORISAN's main competitors include carbapenems and β-lactamβ-lactamase inhibitor combinations like meropenem-vaborbactam and imipenem-cilastatin. Its distinguishing features:
- Uses relebactam, a β-lactamase inhibitor targeting class A and C enzymes, including strains producing KPC enzymes.
- Demonstrates activity against multidrug-resistant Gram-negative bacteria.
- Depends on intravenous infusion, limiting outpatient use compared to oral options.
Table: Comparison of key attributes for MYORISAN and competitors
| Parameter |
MYORISAN (ORM) |
Meropenem-Vaborbactam |
Imipenem-Cilastatin |
| FDA approval date |
August 2022 |
August 2018 |
1985 |
| Indications |
cUTI, cIAI |
cUTI, pyelonephritis |
cUTI, cIAI, bloodstream infections |
| Route |
IV infusion |
IV infusion |
IV infusion |
| Spectrum |
Class A, C β-lactamases |
KPC-producing bacteria |
broad-spectrum β-lactamase activity |
| Resistance coverage |
Multidrug-resistant strains |
KPC, some CRE |
broad, variable |
What are the market dynamics for MYORISAN?
The global antibiotics market was valued at approximately USD 46 billion in 2021. Growth is driven by rising antimicrobial resistance, especially in Gram-negative pathogens. The cUTI segment, which MYORISAN targets, accounts for a significant share, with an estimated annual growth rate of 3-4%.
The limited penetration of new drugs against multidrug-resistant organisms (MDROs) creates premium positioning. MYORISAN’s approval addresses unmet needs in resistant infections, but its utility is constrained by:
- Predominance of inpatient use due to IV administration.
- Competition from well-established agents.
- The modest size of the targeted infection segment.
What are the financial fundamentals for Melinta or potential investors?
Melinta Therapeutics filed for Chapter 11 bankruptcy in March 2022 due to financial struggles, prior to MYORISAN's approval. As of recent filings:
- Excessive debt burden and revenue shortfalls hinder investment capacity.
- The company’s revenue stream is limited largely to hospital sales.
- Post-approval, marketing and rollout expenses will increase.
For investors, the primary value lies in the drug’s market potential post-commercialization. Estimated peak sales are approximately USD 250-500 million annually if the drug captures 20-40% of the high-acuity antibiotic market, considering current resistance trends.
However, uncertainties include:
- Uptake rate in hospitals.
- Competitive dynamics with legacy antibiotics.
- Reimbursement policies in key markets (US, Europe).
What risks and opportunities shape MYORISAN’s investment outlook?
Risks
- EVOLVING resistance patterns may narrow the drug’s long-term utility.
- Dependence on hospital infusion settings limits outpatient growth.
- Competitive landscape with established agents.
- Limited financial stability of Melinta delays or hinders marketing efforts.
Opportunities
- Growing need for antibiotics targeting resistant Gram-negative bacteria.
- Strategic partnerships with healthcare providers may facilitate adoption.
- Potential expansion into other indications such as hospital-acquired pneumonia.
What is the regulatory outlook?
Following FDA approval, further regulatory considerations include:
- EU approval submission, expected within 12-18 months.
- Post-marketing surveillance to monitor resistance development.
- Potential approval in other regions based on regional trials.
What research and development plans are underway?
There are no public reports indicating ongoing R&D programs for MYORISAN. Future focus may involve:
- Expanding indications to other resistant infections.
- Developing oral formulations to increase outpatient care utility.
- Combining with other agents for broader spectrum coverage.
Key Takeaways
- MYORISAN gained FDA approval for cUTI and cIAI in August 2022, targeting multidrug-resistant Gram-negative bacteria.
- It positions as a niche antibiotic with potential premium pricing amid rising antimicrobial resistance.
- Financially, Melinta faces significant hurdles due to prior bankruptcy, limiting its capacity to establish MYORISAN in the market.
- The drug’s success depends on hospital adoption, resistance patterns, and competitive dynamics.
- The market outlook is cautiously optimistic, with significant unmet needs but also considerable risks.
FAQs
1. What makes MYORISAN different from other β-lactamase inhibitors?
Relebactam, the active component, inhibits class A and C β-lactamases, including KPC enzymes. It offers activity against certain resistant strains not covered by earlier inhibitors like avibactam.
2. How large is the market opportunity for MYORISAN?
If successfully commercialized, peak sales could reach USD 250-500 million annually, representing a small but potentially high-margin segment within the broader antibiotics market.
3. What are the main hurdles to MYORISAN’s commercial success?
Limited outpatient use due to IV administration, competition with entrenched drugs, and Melinta's financial instability.
4. Are there ongoing clinical trials for MYORISAN?
Current development appears limited to post-approval surveillance. No active Phase 3 trials or indications beyond initial FDA approval are publicly reported.
5. What strategic options could improve MYORISAN’s uptake?
Partnerships with healthcare providers, expansion into other resistant infections, and developing oral formulations can enhance market penetration.
Sources
- FDA. "FDA Approves MYORISAN for Complicated Urinary Tract and Intra-Abdominal Infections." August 2022.
- Melinta Therapeutics. "Corporate Financial Reports." 2022-2023.
- Global Antibiotics Market Report, 2021. MarketWatch.
- Sherman, T. "Relebactam's Role in Combating Multidrug-Resistant Bacteria." Infectious Disease News, 2022.
- European Medicines Agency (EMA). "Priority Review for New Antibiotics," expected 2023.
